HONG KONG (Reuters) – Chinese state-owned Sinopharm plans to inject 30 billion yuan ($4.6 billion) in assets into unit Beijing Tiantan Biological Products Corp Ltd
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
